Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

Philogen to attend the European Bispecific and Multispecific Antibody congress in Amsterdam on the 22nd and 23rd of February, 2023

Jan 23, 2023 | Past Events

Philogen announces its attendance at the European Bispecific and Multispecific Antibody congress in Amsterdam. Dr. Roberto De Luca (Head of Antibody Therapeutics at Philochem) is giving a lecture on the 23rd of February 2023 entitled “Engineering Antibody-Cytokine...

Philogen to attend the 7th Annual Next-Gen Immuno-Oncology Conference congress in London on the 9th and 10th of March, 2023

Jan 23, 2023 | Past Events

Philogen announces its attendance at the Annual Next-Gen Immuno-Oncology Conference congress in London. Dr. Roberto De Luca (Head of Antibody Therapeutics at Philochem) is giving a lecture on the 9th of March 2023 entitled “Engineering Antibody-Cytokine Fusion...

Philogen to attend the JP Morgan on January 9-12, 2023 in San Francisco

Dec 7, 2022 | Past Events

Philogen announces its attendance at JP Morgan 2023.   Prof. Dr. Dario Neri, CEO and CSO of Philogen, and Dr. Emanuele Puca, Investor Relations and Business Development, will be available for meeting to explore novel collaboration opportunities.

Philogen to attend Mediobanca 5th MidCap Conference on January 18, 2023 in Milan

Dec 7, 2022 | Past Events

Philogen announces its attendance at the 5th MidCap Conference organised by Mediobanca.   Prof. Dario Neri (CEO and CSO), Laura Baldi (CFO), and Emanuele Puca (Investor Relations) will participate at the event. The objective of the MidCap Conference is to bring the...

Philogen to attend the 13th World ADC conference in London on the 13th and 14th of March, 2023

Dec 7, 2022 | Past Events

Philogen announces its attendance at World ADC2023 in London. Dr. Samuele Cazzamalli (Head of Small Molecule Therapeutics at Philochem) is giving a lecture on the 14th of March 2023 entitled “Enhancing the Therapeutic Index of ADCs to Penetrate Solid Tumours:...

Philogen to attend the Antibody Engineering & Therapeutics on December 4-8, 2022 in San Diego

Dec 3, 2022 | 2022, Past Events

Philogen announces its attendance at the Antibody Engineering & Therapeutics 2022. Prof. Dario Neri, CEO and CSO of Philogen, is giving a lecture entitled “Small Molecule-drug Conjugates (SMDCs) and Antibody-drug Conjugates (ADCs): A Comparative Evaluation” Please...
« Older Entries

Recent Posts

  • 20 marzo 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • Philogen to attend the 74th Mosbacher Kolloquium in Mosbach/Baden, on March 23-25, 2023
  • Philogen to attend AACR Annual Meeting in Orlando on April 14-18, 2023
  • Philogen to attend Mid & Small | London 2023 Conference on April 20, 2023
  • Philogen to attend 19th EADO Congress on April 20-22, 2023

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it